Please assess the completion status of the following clinical trial:

Trial Title: PTH Analog Type II Odontoid Fracture

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or older at time of consent \[treatment subjects\] or age 50 years or older at time of fracture (historical control subjects)~* Anderson and D'Alonzo type II dens fracture identified on cervical spine CT, with or without a C1 ring injury. Type II dens fractures are defined as involving the area of the dens between the inferior aspect of the anterior C1 ring and not extending into the superior articular facets of C2 \[all subjects\]~* Fracture is deemed amenable to non-operative treatment by treating fellowship trained spine surgeon \[treatment subjects only\]~* Fracture occurred within the 3 weeks before consent \[treatment subjects only\]~* Report of \>=12 months of amenorrhea within the last year if the patient is female treatment subjects only\]~* Fracture injury occurred within 10 years before consent \[historical control subjects only\]~* The patient completed 12 (+/-1) weeks of hard collar immobilization \[historical control subjects only\]~Exclusion Criteria:~* Personal history of radiation therapy or accidental environmental exposure \[treatment subjects only\]~* Personal history of osteosarcoma \[treatment subjects only\]~* Personal history of Paget's disease \[treatment subjects only\]~* Personal history of bone metastases or skeletal malignancy \[treatment subjects only\]~* Hereditary disorders predisposing to osteosarcoma \[treatment subjects only\]~* Prior teriparatide or abaloparatide use \[treatment subjects only\]~* Any history of prior teriparatide or abaloparatide use \[historical control subjects only\]~* Use of denosumab within the past year \[all subjects\]~* Psychological impairment that precludes following hard collar immobilization recommendations \[treatment subjects only\]~* Ineligible based on history of active or recurrent kidney stones, Comprehensive Metabolic Panel, PTH, Phos results to be determined on a case-by-case basis by an endocrinologist on the study team \[treatment subjects only\]

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)
- Historical control group (Type: ACTIVE_COMPARATOR): Patients who received only 12 weeks of hard collar immobilization

Based on this trial design, predict the completion outcome and termination type (if applicable).